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Abstract: Cannabinoids such as Cannabis-based medicinal extracts (CBMEs) are increasingly 
being used in the treatment of spasticity associated with multiple sclerosis (MS). They have 
been shown to have a beneficial effect on spasticity; however, this evidence is largely based 
on subjective rating scales. Objective measurements using the Ashworth scale have tended to 
show no significant effect; however, the validity of this scale has been questioned. The avail-
able clinical trial data suggest that the adverse side effects associated with using CBMEs are 
generally mild, such as dry mouth, dizziness, somnolence, nausea and intoxication. However, 
most of these trials were run over a period of months and it is possible that other adverse side 
effects could develop with long-term use. There may be reason to be concerned about the use 
of therapeutic cannabinoids by adolescents, people predisposed to psychosis and pregnant 
women.
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Introduction
The discovery in the late 1980s that the main psychoactive constituent of the Cannabis 
sativa plant, ∆9-tetrahydrocannabinol (∆9-THC), acts on a specific cannabinoid 
receptor in the brain (the ‘cannabinoid CB1 receptor’), had an enormous impact on 
the development of cannabinoids as therapeutic drugs.1 Together with the discovery 
of endogenous ligands (‘endocannabinoids’) for this and a second subtype of 
cannabinoid receptor (the ‘CB2 receptor’), such as anandamide (arachidonyletha-
nolamide) and 2-arachidonylglycerol (2-AG),1 considerable interest has been gener-
ated in the possibility that either natural or synthetic cannabinoids might be used to 
modulate the endogenous cannabinoid system for therapeutic purposes. One area of 
clinical application has been the treatment of pain and spasticity in multiple sclerosis 
(MS). This review will focus specifically on the potential of cannabinoids to relieve 
spasticity in MS.
Preclinical animal studies suggest that cannabinoids have anti-spastic effects. 
Since CB1 receptors appear to be located mainly presynaptically and inhibit calcium 
influx at axon terminals, they are ideally positioned to inhibit the release of classical 
neurotransmitters such as glutamate.2,3 Activation of CB1 receptors also decreases 
neuronal excitability by activating somatic and dendritic potassium channels.2 
Using the experimental allergic encephalomyelitis (EAE) mouse model of MS, 
cannabinoids have been reported to reduce both spasticity and tremor; furthermore, 
changes in CB1 receptors have been found in the CNS of EAE animals.4–6 This has Therapeutics and Clinical Risk Management 2010:6 60
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led to the proposal that endocannabinoids provide a natural, 
anti-spastic function in the CNS.7
Clinical trial evidence
Although many patients with MS use Cannabis in order to 
obtain relief from chronic pain and spasticity,8–10 until recently 
there were few reliable clinical data to demonstrate whether or 
not it has any effect beyond that of a placebo. The first clinical 
studies of the effects of ∆9-THC on spasticity in MS were 
not encouraging. Most of these studies used small sample 
sizes and ∆9-THC generally had no effect when objective 
measurements were made.11,12 Nonetheless, some patients 
did report a subjective improvement in symptoms.
The first systematic, placebo-controlled, clinical trial of 
the effects of ∆ 9-THC on MS was published by Killestein and 
colleagues in 2002.13 Killestein et al evaluated the effects of 
oral ∆ 9-THC (2 × 2.5 mg per day; maximum 2 × 5 mg) and a 
Cannabis sativa plant extract on 16 MS patients with severe 
spasticity. They quantified spasticity using the Ashworth scale 
and disability using the Expanded Disability Status Scale 
(EDSS). Neither the ∆9-THC nor the Cannabis extract sig-
nificantly reduced spasticity compared to the placebo; how-
ever, the Cannabis extract was associated with significantly 
more adverse side effects. Furthermore, both ∆9-THC and 
the Cannabis extract worsened the patients’ global impres-
sion of their condition. The ∆9-THC doses used were low by 
comparison with later studies; however, they were obviously 
high enough to produce adverse side effects.
In 2001, the Cannabinoids in Multiple Sclerosis 
(CAMS) trial was initiated in the UK. This was a blind, 
placebo-controlled study, coordinated by Derriford Hospital 
in Plymouth. The trial involved 660 MS patients receiving 
either 0.25 mg/kg ∆9-THC (dronabinol, administered orally 
in 2.5 mg capsules), natural Cannabis oil (Cannador) or a 
placebo, and measurements of spasticity, pain and tremor 
were performed. Some patients were also monitored for 
cognitive side effects. The first of these results was published 
in 2003 by Zajicek and colleagues.14 Patients were treated 
either with an oral Cannabis extract (n = 213), ∆9-THC 
(n = 206) or placebo (n = 213) for 15 weeks and spasticity 
was quantified using the Ashworth scale. The maximal daily 
dose was 25 mg. The Cannabis extract contained 2.5 mg of 
∆9-THC, 1.25 mg of cannabidiol (CBD) and less than 5% of 
other cannabinoids. When the placebo was compared with 
the Cannabis extract, and with ∆9-THC, the mean reduction 
in the Ashworth scores was not statistically significant (0.32 
and 0.94 respectively). Nonetheless, there was a significant 
reduction in patient-reported spasticity. While only 46% of 
patients on the placebo reported an improvement in spasticity, 
61% and 60% of patients receiving the Cannabis extract 
or ∆9-THC (respectively) reported an improvement. These 
results were reminiscent of the Killestein and colleagues’13 
study in which patients reported subjective improvement even 
when objective measurements of spasticity did not indicate 
any difference. Adverse side effects were generally minor and 
similar between the placebo, Cannabis extract and ∆9-THC 
groups. In a 12-month follow-up study of 657 patients, 
Zajicek and colleagues15 reported that ∆9-THC had a signifi-
cant effect on spasticity according to the Ashworth scale. The 
mean decrease was 1.82 (n = 154) compared to the Cannabis 
extract (mean decrease: 0.1, n = 172) and the placebo groups 
(mean decrease: 0.23, n = 176). No major adverse effects were 
reported. It is possible that ∆9-THC had a greater effect on 
the patients’ Ashworth score over time as a result of plasticity 
in the endocannabinoid system.
Wade and colleagues16 performed a double-blind, placebo-
controlled, single patient crossover trial involving whole plant 
extracts of ∆9-THC, CBD or 1:1 CBD: ∆9-THC. The trial 
included 24 MS patients, 4 patients with spinal cord injury, 
1 with brachial plexus damage and another with limb amputa-
tion. They reported that ∆9-THC and CBD improved spasticity, 
but once again there were no significant differences using the 
Ashworth scale. Three patients experienced transient hypoten-
sion and intoxication at the beginning of the treatment.
In a further study, Wade and colleagues17 reported the 
effects of a Cannabis based medicinal extract (CBME, ie, 
Sativex®) on 80 patients with MS. The trial was random-
ized, placebo-controlled and double-blind and the drug was 
delivered by oromucosal spray (2.7 mg ∆9-THC and 2.5 mg 
CBD at each actuation). The patients were allowed to self 
titrate their doses to achieve the best effect, with maximal 
doses of 120 mg ∆9-THC and CBD per day. Spasticity was 
assessed using a visual analogue scale (VAS) and a modi-
fied Ashworth scale. At 6 weeks, the VAS scores showed a 
significant reduction in the patients (n = 39) whose primary 
symptom had been spasticity. However, once again the Ash-
worth scale data were not significantly different between the 
CBME and placebo groups. The most common adverse side 
effects were intoxication and a decrease in lower limb tone 
and these could be resolved by a reduction in dose. Overall, 
the results suggested that cannabinoids might be useful for 
spasticity in specific types of MS patients.18
Vaney and colleagues19 reported a double blind, placebo-
controlled, crossover study of 57 MS patients receiving 
Cannabis-based oral capsules containing 2.5 mg ∆9-THC and 
0.9 mg CBD. The dose escalated, with the maximal daily dose Therapeutics and Clinical Risk Management 2010:6 61
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of 30 mg ∆9-THC. Efficacy against spasticity was assessed 
using self report of spasm frequency and the Ashworth 
Scale. For the 50 patients included in the entire intention-
to-treat set, there were no significant differences. However, 
for 37 patients who received 90% of their prescribed dose, 
significant improvements in spasm frequency were observed. 
Adverse side effects such as dry mouth and blurred vision were 
slightly more frequent in the active treatment group. In a study 
primarily directed at lower urinary tract symptoms (LUTS), 
Brady and colleagues20 also reported that the self assessment 
of spasticity showed a significant improvement, even with a 
∆9-THC only extract, and with only minor side effects.
Collin and colleagues21 conducted a 6 week, double blind, 
placebo-controlled trial comparing Sativex and placebo 
in 199 MS patients. Using a numerical rating scale, they 
reported a significant decrease in spasticity in the Sativex 
group compared to placebo. However, they also found that 
dizziness, blurred vision and impaired attention were more 
common in the Sativex group.
Wissel and colleagues22 studied the effects of the synthetic 
cannabinoid, nabilone (1 mg/day), on pain related to spastic-
ity in a placebo-controlled, crossover trial in 11 patients with 
chronic upper motor neurone syndrome. They found that 
pain was significantly reduced; however, spasticity was not, 
suggesting that even though pain may be spasticity related, 
spasticity itself is not necessarily reduced by cannabinoids.
In the most recent randomized, double-blind, placebo-
controlled trial, Hagenbach and colleagues23 evaluated the 
effects of ∆9-THC on patients with spasticity related to spinal 
cord injury. They used a spasticity sum score using a modified 
version of the Ashworth scale and found a significant decrease 
in spasticity in the ∆9-THC group; however, 15–20 mg ∆9-
THC per day were needed to achieve this effect.
Shakespeare and colleagues24 have suggested that many 
commonly used anti-spasticity drugs have also failed to 
result in statistically significant differences according to the 
Ashworth scale and that some drugs may produce clinically 
meaningful changes in spasticity that the Ashworth scale is 
incapable of detecting.
Another issue is the heterogeneity of the patients studied 
in some of these clinical trials. The effects of cannabinoids on 
spasticity caused by MS versus other conditions such as upper 
motor neurone syndrome, are not necessarily comparable.
Adverse effects of cannabinoids 
used in clinical trials
In most cases, the route of administration used has been 
oral or by some form of aerosol spray, thereby avoiding any 
adverse effects associated with smoking Cannabis. Most of 
these studies have been conducted over a period of months 
and therefore do not necessarily provide information on pos-
sible long-term adverse effects of the use of cannabinoids. 
Nonetheless, they do provide a reasonable estimate of the 
most likely side effects associated with the use of ∆9-THC 
or ∆9-THC/CBD over a period of months.
It is well established that ∆9-THC can adversely affect 
cognitive function with a sufficiently high dose.11 The ques-
tion really is whether such adverse effects occur at the doses 
of ∆9-THC or a synthetic cannabinoid that would be used 
therapeutically, especially over the long-term. Although 
there have been some reports of attentional disturbances, 
increased reaction time and impaired spatial working memory 
in clinical trials of the CBMEs, these have been rare and, in 
general, there have been few reports of cognitive dysfunc-
tion.17,19,20,25–27 In one of the few systematic studies of the 
possible adverse side effects of cannabinoids, Aragona and 
colleagues28 conducted an 8-week, randomized, double-blind, 
placebo-controlled, parallel-group crossover trial of Sativex, 
using 17 Cannabis-naïve patients with MS. They assessed 
adverse cognitive events over a 3-week period using various 
checklists and the Paced Auditory Serial Additional Test and 
found no evidence of significant cognitive impairment at 
the doses used. These results suggest that the regular use of 
CBMEs for the treatment of MS may not result in significant 
cognitive impairment, unless there is an interaction with other 
drugs or the cognitive effects of the disease state.
Another common concern is whether cannabinoid treat-
ment might exacerbate depression or psychosis. Although it 
was not reported in the most recent clinical trials, a common 
reason for withdrawal from earlier clinical trials investigat-
ing the use of cannabinoids to control pain and nausea, was 
dysphoria.29,30 Nonetheless, while there is evidence that the 
use of Cannabis itself can increase the risk of psychiatric 
disorders,31,32 especially in adolescents, there is very little 
evidence that the use of therapeutic cannabinoids can have 
such effects, at the doses prescribed. In the study by Aragona 
and colleagues,28 they also assessed psychological state over 
3 weeks of treatment with Sativex and found no evidence of 
psychopathology at the doses used. Nonetheless, many MS 
patients take beta-interferon, which can cause depression as 
a side effect, and it is conceivable that cannabinoids could 
potentiate this effect.
There is increasing evidence to suggest that the use of 
Cannabis during pregnancy can have a lasting negative 
impact on the fetal nervous system, resulting in deficits in 
attention, visual analysis and hypothesis testing.33–38 While Therapeutics and Clinical Risk Management 2010:6 62
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there is no evidence at present that cannabinoids used for 
therapeutic purposes can have this effect, this issue remains 
unresolved.
Dizziness is a commonly reported side effect in clinical 
trials of cannabinoids.27,28 This has often been attributed to 
the cardiovascular effects of ∆9-THC; however, vertigo, the 
sensation of self-motion, is distinct from general dizziness 
and implies a vestibular cause. In fact, CB1 receptors exist 
in the brainstem vestibular nucleus and the synthetic CB1 
receptor agonist, CP-55,940, has been shown to modulate 
the firing rate of vestibular nucleus neurons.39,40 These results 
suggest that cannabinoids have the potential to cause dizzi-
ness and vertigo by acting on the vestibular nucleus, although 
they are not likely to be major problems.
Cannabis extracts versus synthetic 
cannabinoids
At present, most clinical studies of the effects of cannabinoids 
on spasticity in MS have used either ∆9-THC or a CBME that 
contains ∆9-THC, rather than a synthetic cannabinoid recep-
tor agonist. One reason for using CBMEs such as Sativex 
is that it is claimed that the CBD in the extract has specific 
effects on spasticity.25,26 Nonetheless, ∆9-THC is a weak 
partial agonist at CB1 and CB2 receptors and therefore has 
less selective effects than a synthetic selective CB1 recep-
tor agonist.1 Pryce and Baker41 have in fact reported that 
it is CB1 receptors that mediate the anti-spastic effects of 
cannabinoids. CBD, on the other hand, acts on anandamide 
hydrolysis/reuptake and cytokines. Of concern is the lack 
of understanding of the effects of some of the constituents 
of Cannabis. Whalley et al42 compared standard Cannabis 
extracts (SCEs) with and without ∆9-THC, and reported that 
while ∆9-THC depressed evoked depolarizing post-synaptic 
potentials (PSPs) in rat olfactory cortex neurons, SCEs with 
and without ∆9-THC could potentiate PSPs. This effect was 
blocked by the CB1 receptor antagonist, SR141716A. One 
of the intriguing findings was that the potentiation of PSPs 
was greater when a ∆9-THC-free SCE was used. The authors 
speculated that a novel, unknown component in Cannabis 
may over-ride the decrease in excitatory synaptic transmis-
sion caused by∆9-THC, and that this constituent may be 
responsible for the pro-convulsant effects of Cannabis that 
have sometimes been reported. In another study by Wilkinson 
et al,43 using seizure activity induced in rat piriform cortical 
brain slices by oxotremorine-M, found that an SCE had a 
more potent anticonvulsant action than ∆9-THC alone, but 
that the ∆9-THC-free extract also had anticonvulsant activity. 
CBD, by contrast, had no anticonvulsant effect.
Even synthetic CB1 receptor agonists may have variable 
effects in the CNS, as a result of their action at different 
CB receptors and individual variability in CB receptor 
expression.44
Conclusion
The therapeutic effects of CBMEs on spasticity that have 
been reported in clinical trials could best be described as 
moderate and occurred mainly in subjective scores rather than 
objective measurements. Therefore, the therapeutic benefit 
from these drugs may be quite small in return for any adverse 
side effects that are experienced. Systematic, dose-to-dose 
comparisons with other anti-spastic drugs such as baclofen 
have not yet been made; therefore, it is not clear how much 
therapeutic advantage CBMEs will offer over conventional 
medications. The clinical trials to date do not indicate seri-
ous adverse side effects associated with the use of CBMEs; 
however, it remains to be seen whether other adverse events 
appear with long-term use. Nonetheless, it must be noted 
that the available evidence from clinical trials suggests that 
many of the adverse effects of cannabinoids decrease with 
continued use. In this respect, it is important to note that 
while ∆9-THC acts as a partial agonist at cannabinoid CB1 
receptors, most synthetic agonists, such as CP55,940 and 
WIN 55,212-2, act as full agonists and are therefore likely 
to have more potent effects. On the basis of currently avail-
able data, CBMEs seem unlikely to have serious, long-term 
adverse effects on cognition or mood. However, there may 
be reason to be concerned about the effects of CBMEs on 
adolescents, people predisposed to psychosis, and the fetal 
nervous system.
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